Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Atopic Dermatitis: KOL Insight [2018]

Product Code:
596201055
Publication Date:
August 2018
Format:
PDF + PPTX
Price:
£6,795

Will new pipeline therapies transform the treatment of atopic dermatitis?

New pipeline agents look set to transform the treatment of moderate-to-severe atopic dermatitis. Dupixent (dupilumab; Regeneron/Sanofi) has revolutionised the treatment of this disease, but as the market evolves, and more treatments are approved, clinical and commercial differentiation will become key. Key opinion leaders expect the oral JAK inhibitors such as Olumiant (baricitinib; Eli Lilly/Incyte) and PF 04965842 to impact the treatment paradigm, while IL-13 monoclonal antibodies, tralokinumab (AstraZeneca/Leo Pharma) and lebrikizumab (Dermira), could provide alternative treatment options. Moreover, other pipeline programmes such as nemolizumab (anti-IL-31R; Galderma/Chugai) and etokimab (anti-IL-33; AnaptysBio) could potentially become niche options for certain patient subgroups.Meanwhile, in the mild-to-moderate atopic dermatitis space, experts provide insights on Eucrisa (crisaborole; Pfizer) as well as new topical JAK inhibitors and topical PDE4 inhibitors being evaluated. Twelve US and EU KOLs offer their candid insights on these issues and more.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • Dupixent has transformed the treatment of moderate-to-severe atopic dermatitis. How is this product currently being prescribed and what additional clinical trials are considered important? 
  • Pfizer’s Eucrisa has been on the US market since 2017 and a filing has been submitted in Europe. How do KOLs view this product and how will prescribing change in the future?  
  • Several oral JAK inhibitors are in late-stage development. With several JAK inhibitors in late-stage development, differentiation will be key. But do KOLs have any concerns? Or will the convenience of oral treatment be sufficient to support clinical adoption?
  • How will AstraZeneca/Leo Pharma’s tralokinumab and Dermira’s lebrikizumab impact the treatment paradigm? What do experts think of the data reported so far for these anti-IL-13 monoclonal antibodies?
  • Will Galderma/Chugai’s nemolizumab succeed in carving out a niche for the treatment of atopic dermatitis? What are the perceived advantages/disadvantages of this anti-IL-31 monoclonal antibody?
  • AnaptysBio has reported early-stage data for etokimab (ANB 020), an IL-33 monoclonal antibody. What are KOLs’ reactions to these results and how do they expect etokimab to be positioned in the treatment algorithm?
  • Several topical therapies are being evaluated as potential therapies for mild-to-moderate disease. Will these topical JAK inhibitors and topical PDE4 inhibitors address the need for alternatives to topical corticosteroids?
Request sample pages

Back to the top

Quotes

“I think we will have a lot of development, a lot of opportunities for patients, a change also in the way we understand and we treat the disease. So it's a very fruitful and promising period for patients and for physicians.”
EU Key Opinion Leader

“Dupixent has done so much for quality of life. It is hugely important to these people. I don't know anyone who wants to give it up. We've had occasional patients who got clear and stopped taking it and stayed clear so that may not have to be a life-long process.” 
US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Dupixent (dupilumab; Regeneron/Sanofi)
  • Eucrisa (crisaborole; Pfizer)

Pipeline (Phase 3) Therapies

  • tralokinumab (AstraZeneca/Leo Pharma)
  • Olumiant  (baricitinib; Eli Lilly/Incyte)
  • PF 04965842 (Pfizer)

Pipeline (Phase 2) Therapies

  • lebrikizumab (Dermira)
  • nemolizumab (Galderma/Chugai)
  • ALX 101 (Ralexar Therapeutics)
  • GBR 830 (Glenmark)
  • tezepelumab (Amgen/AstraZeneca)
  • etokimab (AnaptysBio)
  • anti-GATA3 gene therapy (Sterna Biologicals)
  • Jakafi/Jakavi (topical ruxolitinib; Incyte)
  • upadacitinib (AbbVie)
  • lotamilast (Roivant Sciences)
  • difamilast (Otsuka/Medimetriks)

KOLs interviewed

KOLs from North America

  • Prof. Donald YM Leung, MD is Professor and Head of the Division of Pediatric Allergy and Immunology, Department of Pediatrics at University of Colorado Denver School of Medicine, Denver, United States.
  • Prof. Joseph F Fowler Jr, MD, is Clinical Professor of Dermatology at the University of Louisville School of Medicine, Louisville, KY, United States.
  • Prof. David M Pariser, MD, is Professor of Dermatology at Eastern Virginia Medical School, Virginia, United States.
  • Prof. Peck Y Ong, MD, is Associate Professor of Allergy and Immunology at the Pediatric Medicine University of Southern California, California, United States.
  • Prof. Jon M Hanifin, MD, Professor of Dermatology at Oregon Health & Science University, Oregon, United States.
  • Anonymous, US KOL, is Professor of Dermatology at a leading US institute.

KOLs from Europe

  • Prof. Richard Warren, BSc, MBChB, MRCP, PhD, is Professor of Dermatology and Consultant Dermatologist at Salford Royal NHS Foundation Trust; and Director of the Dermatopharmacology Unit at the University of Manchester, UK.
  • Prof. Graham Ogg, MA, Dphil, BMBCh, FRCP, is MRC Programme Leader and Professor of Dermatology at University of Oxford; and Consultant Dermatologist at Oxford University Hospitals NHS Trust, Oxford, UK.
  • Prof. Alain Taïeb, MD, is Professor of Dermatology and Head of the Department of Dermatology and Pediatric Dermatology at Bordeaux University Hospitals, Bordeaux, France.
  • Prof. Carle Paul, MD, PhD, is Professor and Chairman of the Department of Dermatology at Paul Sabatier University, Toulouse, France.
  • Anonymous, German KOL, is Professor of Allergy and Immunology at a leading German university hospital.
  • Anonymous, German KOL, is Professor of Dermatology at a leading German university.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.



customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved